On Tuesday (28/06) Duta Intidaya became the 7th company to list on the Indonesia Stock Exchange (IDX) in 2016. The company, an Indonesia-based health & beauty products retailer and specifically known for being the operator of the Watsons stores in Indonesia, made a solid trading debut. Its shares rose five percent to finish at IDR 189 per piece. Through the initial public offering (IPO), Duta Intidaya seeks new funds for business expansion and debt settlement. The company is set to open new branches and expand its e-commerce activities.

Read more ›

For its raw materials the pharmaceutical industry of Indonesia is highly dependent on imports. Around 90 percent of medicines' raw materials, roughly IDR 7 trillion (approx. USD $526 million), may be imported this year. Meanwhile, given the Indonesian government is eager to develop its universal health care program (launched in 2014), demand for pharmaceutical products in Indonesia is expected to rise further. Total clients under the national health insurance program is expected to rise from 162 million in 2015 to 186 million in 2016. By the year 2019 the government wants to provide universal health care to all Indonesians.

Read more ›

There is a growing mismatch between claims paid and premiums received by Indonesia's Healthcare and Social Security Agency (Badan Penyelenggara Jaminan Sosial, or BPJS Kesehatan). This year the deficit could reach IDR 9.8 trillion (approx. USD $731 million), leading to concern about the financial sustainability of the program and the need to search for additional and innovative ways to fund Indonesia's National Health Insurance (Jaminan Kesehatan Nasional, or JKN) program.

Read more ›

In one of the next economic stimulus packages of the Indonesian government the focus will be on increasing domestic production of raw materials for medicines and medical devices. Currently, these industries are still highly dependent on imports of raw materials. It is estimated that around 90 percent of raw/basic materials for medicines and medical devices need to be imported from abroad and therefore cause additional pressure on Indonesia's balance of payments.

Read more ›

RSM Indonesia, one of Indonesia's leading audit, tax and financial advisory firms, expects to see more mergers and acquisitions (M&A) in Indonesia in 2016 due to the improving global and domestic economic conditions, a stable rupiah exchange rate, and Indonesian's growing purchasing power. For foreign investors a M&A deal is one of the strategies to enter Indonesia. Up to early November, the total value of M&A deals in Indonesia in 2015 stood at USD $3.53 billion.

Read more ›

On the latest shareholder meeting (conducted Wednesday 23 September) it was decided that Indonesian hospital operator Mitra Keluarga Karyasehat can go-ahead with its planned 10:1 stock split. The company wants to reduce its shares’ nominal value by ten in order to boost liquidity as shares become more affordable. Meanwhile, shareholders also agreed to boost the company’s paid up capital. After Siloam International Hospitals, Mitra Keluarga Karyasehat is Indonesia’s second-largest hospital operator.

Read more ›

The United Nations Children's Fund (UNICEF) stated in a recently published report that Indonesia has made significant progress in reducing the country’s child mortality rate. According to the report, entitled “Committing to Child Survival: A Promise Renewed (Progress Report 2015)", Indonesia’s mortality rate for children below the age of five years currently stands at 27 deaths per 1,000 births, a significant improvement from the 85 deaths per 1,000 births that was recorded in 1990.

Read more ›

Indonesian pharmaceutical company Merck, controlled by German consumer healthcare Merck Holding GmbH, plans to conduct a stock split in 2015 in a move to boost liquidity as well as increase trading of the company’s shares. Merck is currently discussing the stock split plan with the Indonesia Stock Exchange (IDX) and the Financial Services Authority (OJK). Bambang Nurcahyo, Finance Director at Merck, said that the ideal ratio for the split is 1:20. An extraordinary general meeting (to discuss the plan) will be held in mid-2015.

Read more ›

On Tuesday (24/03), Indonesian hospital operator Mitra Keluarga Karyasehat became the second company to list on the Indonesia Stock Exchange (IDX) in 2015. It turned out to be a highly successful initial public offering (IPO) as the company’s shares surged 24.7 percent on its trading debut, reflecting investors’ solid confidence in healthcare stocks. Mitra Keluarga, subsidiary of pharmaceutical company Kalbe Farma, raised IDR 4.4 trillion (USD $341 million), hence constituting the largest IPO since Garuda Indonesia’s IPO in 2011.

Read more ›

Shares of Kalbe Farma, Indonesia’s largest pharmaceutical company, have been under pressure over the past couple of days due to the deaths of two hospital patients after they had taken a medicine manufactured by Kalbe Farma. According to the Indonesian Pharmacy Association (GP Farmasi Indonesia) Buvanest Spinal, an anesthetic, was wrongly packaged and hence did not contain bupivacaine but instead tranexamic acid, which aims to stop or reduce heavy bleeding (usually used during surgery).

Read more ›

Mitra Keluarga Karyasehat, a leading Indonesian hospital operator and subsidiary of the Kalbe Group, plans to raise about IDR 4.2 trillion (USD $328 million) in an initial public offering (IPO) on the Indonesia Stock Exchange (IDX) in March 2015. The company plans to offer up to 261.9 million shares, or 18 percent of its enlarged equity, to the public. Five percent of this total constitute new shares, while 13 percent are shares divested by private equity firm Lion Investment Partners.

Read more ›

On Monday (23/06), the World Bank released its latest analysis regarding the Indonesian economy. In its report, titled ‘Indonesia: Avoiding the Trap’, the World Bank states that Indonesia needs to implement a six reforms in priority areas in order to avoid the so-called middle income trap (referring to the situation where a country gets stuck at a certain income level). Without these critical reforms, the country’s economic growth will slow and may not be able to escape the middle income trap.

Read more ›

Imports of oil will accelerate to 1.6 million barrels per day (bpd) by 2020 if fuels continue to be subsidized by the Indonesian government. This development will seriously burden Indonesia's trade balance (and current account). In 2013, Indonesia posted a trade deficit of USD $12.6 billion in the oil & gas sector. Due to improved performance in the non-oil & gas sector, the overall trade deficit was kept at USD $4.06 billion. Besides placing downward pressure on the rupiah exchange rate, expensive subsidies also burden the state budget.

Read more ›

The inflation rate of Indonesia rose slightly in November 2013 (month-to-month) and confirms estimations that inflation in Southeast Asia's largest economy is under control after having accelerated sharply due to the introduction of higher subsidized fuel prices June 2013. In recent months, inflation moved sideways and is expected to ease considerably in the first quarter of 2014. Indonesia's consumer price index rose 0.12 percent in November due to rising electricity, processed foods and health care costs.

Read more ›